Q-omics provides the consensus-scored IARS2 profile across patient tissues and cancer cell-line models. IARS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IARS2 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, IARS2 protein abundance shows 32,646 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where IARS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IARS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IARS2 survival associations across molecular data types. IARS2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IARS2 RNA expression–survival associations across cancer types. High IARS2 expression shows unfavorable associations in CESC, ACC, BLCA and PAAD, but favorable associations in KIRC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IARS2 RNA expression.
This table summarizes IARS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 11. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IARS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IARS2 shows higher tumor expression in LUAD, HNSC, BLCA, LIHC, LUSC and STAD. The LUAD box plot shows higher IARS2 RNA expression in tumor versus normal tissue (log2 FC = +1.424, t-test p < 0.001).
This table shows molecular features associated with IARS2 in patient tissues and cancer cell lines. In patient samples, IARS2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IARS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
